<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03963024</url>
  </required_header>
  <id_info>
    <org_study_id>2013-002479-16</org_study_id>
    <nct_id>NCT03963024</nct_id>
  </id_info>
  <brief_title>Treosulfan-TMI Conditioning and Rapamycin GvHD Prophylaxis Before Allo-HSCT</brief_title>
  <acronym>TrRaMM-TMI</acronym>
  <official_title>Treosulfan and Total-marrow Irradiation (TMI) Based Conditioning With Rapamycin Based Graft vs. Host Disease (GvHD) Prophylaxis for Allogenic Stem Cell Transplantation (Allo-HSCT) in Patients With High-risk Hematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS San Raffaele</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS San Raffaele</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      TrRaMM-TMI is a phase I trial to evaluate the feasibility and efficacy of an original
      sequential TMI/TrRaMM (Total Marrow Irradiation/Treosulfan-Rapamycin-Mycophenolate Mofetil)
      schedule in patients with hematological malignancies in advanced stage of disease undergoing
      an allogenic Stem Cell Transplant (SCT).

      The aim is to determine the maximum tolerated dose of TMI when combined with conditioning
      chemotherapy to transplant according to TrRaMM schedule.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 12, 2014</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the maximum tolerated dose of TMI (FEASIBILITY of TMI)</measure>
    <time_frame>From administration of TMI (-5) to transplant</time_frame>
    <description>To determine the maximum tolerated dose of TMI when combined with conditioning chemotherapy to transplant according to TrRaMM schedule</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Survival post transplant</measure>
    <time_frame>+30 days post transplantation</time_frame>
    <description>Evaluation of survival and engraftment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy - progression free survival (PFS)</measure>
    <time_frame>End of total follow-up is 365 days after transplantation of the last patient included</time_frame>
    <description>PFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy - Overall survival (OS)</measure>
    <time_frame>End of total follow-up is 365 days after transplantation of the last patient included</time_frame>
    <description>OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy - Relapse incidence (RI)</measure>
    <time_frame>End of total follow-up is 365 days after transplantation of the last patient included</time_frame>
    <description>RI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Transplant Safety - incidence of non-relapse mortality (NRM)</measure>
    <time_frame>Eon day +28, day +100 and +360</time_frame>
    <description>Evaluation of incidence of NRM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Transplant Safety</measure>
    <time_frame>End of total follow-up is 365 days after transplantation of the last patient included</time_frame>
    <description>Cumulative of incidence and cumulative severity of GvHD</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Irradiated Bone Marrow</condition>
  <condition>Transplant-Related Hematologic Malignancy</condition>
  <condition>Leukemia, Acute</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Graft Vs Host Disease</condition>
  <arm_group>
    <arm_group_label>Single Arm Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conditioning treatment &quot;Treosulfan+TMI&quot;; SCT; GvHD prophylaxis;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conditioning treatment &quot;Treosulfan-TMI&quot;</intervention_name>
    <description>Treosulfan i.v.: 14 g/m²/d (day -6 to -4) Fludarabine i.v.: 30 mg/m²/d (day -6 to -2) Antithymocyte globulin (ATG)-Fresenius i.v.: 5/0 mg/kg (day -4 to -2) Mabthera i.v.: 200/0* mg/m2 (day -1) TMI: (10 Gy) 2 Gy bis in die (BID) (day -2 to -1) or TMI: (12 Gy) 2 Gy BID (day -3 to -1) or TMI: (14 Gy) 2 Gy BID (day -3 to -1)</description>
    <arm_group_label>Single Arm Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>SCT</intervention_name>
    <description>Stem Cell Transplant</description>
    <arm_group_label>Single Arm Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GvHD prophylaxis</intervention_name>
    <description>Rapamycin p.o.: 4 mg/d, (target 8-15 ng/ml) (starting day -7) Mycofenolate mofetile: 10 mg/kg tid, (Maximum dose 720 mg/tid) (starting from day 0)</description>
    <arm_group_label>Single Arm Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with haematological malignancies such as

               -  any acute myeloid leukemia (AML) beyond Complete Remission (CR) 1

               -  any acute lymphoblastic leukemia (ALL) beyond CR1

               -  multiple myeloma (MM) at any relapse/progression, except refractory disease

               -  MM with unfavourable cytogenetic profile at diagnosis

               -  MM with less than a partial response (PR) after induction therapy

          -  Karnofsky Index ≥ 80 %

          -  Adequate contraception in female patients of child-bearing potential.

          -  Written informed consent

          -  Availability of one of the following:

               -  A matched related or unrelated donor (MRD or MUD)

        Exclusion Criteria:

          -  A hematopoietic cell transplantation-specific comorbidity index &gt; 4

          -  Active non-controlled infectious disease at the moment of inclusion

          -  Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection

          -  Impaired liver function (Bilirubin &gt; 2.0 x upper normal limit; Transaminases &gt; 3.0 x
             upper normal limit)

          -  Impaired renal function (Creatinine-clearance &lt; 60 ml/min; Serum Creatinine &gt; 1.5 x
             upper normal limit).

          -  Pleural effusion or ascites &gt; 1.0 L

          -  Pregnancy or lactation

          -  Known hypersensitivity to treosulfan and/or fludarabine and/or rapamycin

          -  Non-co-operative behaviour or non-compliance

          -  Psychiatric diseases or conditions that might impair the ability to give informed
             consent

          -  Previous spinal cord radiotherapy with dose ≥ 45 Gy equivalent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fabio Ciceri, MD</last_name>
    <phone>0039022643</phone>
    <phone_ext>4289</phone_ext>
    <email>ciceri.clinicaltrials@hsr.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabio Ciceri, MD</last_name>
      <phone>0039022643</phone>
      <phone_ext>4289</phone_ext>
    </contact>
    <investigator>
      <last_name>Andrea Assanelli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 21, 2019</study_first_submitted>
  <study_first_submitted_qc>May 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2019</study_first_posted>
  <last_update_submitted>May 24, 2019</last_update_submitted>
  <last_update_submitted_qc>May 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS San Raffaele</investigator_affiliation>
    <investigator_full_name>Ciceri Fabio</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Treosulfan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

